Latest Breaking News On - European calcified tissue society congress - Page 1 : comparemela.com

Inozyme Pharma To Present Recently Announced Data From Phase 1/2 Trials Of INZ-701 In Adults With ENPP1 Deficiency And ABCC6 Deficiency (PXE) At Upcom

BOSTON, May 23, 2024 (GLOBE NEWSWIRE)

United statesPseudoxanthoma elasticumStefan rileyYves sabbaghMatt peraInozyme pharmaKurt gunterEndocrine society annual meetingExchange commissionEuropean calcified tissue society congressCorporate communicationsCompany or inozymeBoston convention exhibition centerInozyme pharma incClinical public healthMineral metabolism biomarkers

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April –– Phase 1 tr.

United statesDouglasa trecoStefan rileyChristine obrienInozyme pharmaMatt peraSagar nigwekarEuropean calcified tissue society congressCorporate communicationsExchange commissionAmerican society of nephrologyCompany or inozymeKidney research centerInozyme pharma incDevelopment rd expensesPatient registry

Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023 - Inozyme Pharma (NASDAQ:INZY)

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of

United statesInozyme pharmaSagar nigwekarStefan rileyMatt peraResearch advances in boneDrug administrationInozyme pharma incEuropean calcified tissue society congressCorporate communicationsAmerican society of nephrologyKidney research centerExchange commissionMmsc coAmerican societyKidney week

Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate to.

United statesYves sabbaghInozyme pharmaMatt peraKurt gunterStefan rileyDouglasa trecoEuropean medicines agencyEuropean congressExchange commissionCorporate communicationsEuropean calcified tissue society congressDevelopment rd expensesGlobenewswire incPaediatric committeeDrug administration

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomInozyme pharmaSmithsolvematt peraInozyme pharmastefan rileyYves sabbaghInozyme pharma incCorporate communicationsEuropean calcified tissue society congressTrial designtheNorth america